alzheimer’s and young adults | Washington University School of Medicine is leading a trial into the effects of a drug designed to stop Alzheimer’s disease symptoms before they arise. The Primary Prevention Trial is an international study focused on young adults whose families have genetic mutations that make it highly likely they will develop Alzheimer’s as young as 30. Remternetug is an investigational antibody that can remove amyloid beta from the brain and block its accumulation. Researchers hope to find that removing or blocking these plaques while a patient is still asymptomatic will disrupt the early stages of the disease and stop the development of symptoms.
a.i. and imaging
Mercy is using artificial intelligence to provide patients with greater peace of mind. Aidoc technology has been implemented in its imaging services to provide comprehensive additional review alongside the expertise of medical professions. The program recognizes a wide range of suspected conditions, including brain hemorrhage, pulmonary embolism, cervical spine fracture and lung nodules. It also flags possible incidental findings. “By empowering our teams with real-time insights and seamless coordination across specialties, this technology ensures we can focus on delivering exceptional care to every patient, every time,” Mercy president and CEO Steve Mackin says.
covid-19 vaccine advances
A new COVID-19 vaccine based on technology developed at Washington University School of Medicine has entered clinical trials. While most COVID-19 vaccinations are administered in the arm or leg, this one is given nasally. The design induces a strong immunity in the nose and upper respiratory tract, which is where the virus enters the body. This could potentially stop transmission of the disease, as well as reduce serious illness and death. The trial will be sponsored and conducted by the National Institute of Allergy and Infectious Diseases, and initiation of the first phase is planned for this spring.
heart failure treatment
Heart failure is a progressive disease resulting from the heart muscle struggling to efficiently pump blood and deliver oxygen throughout the body. It accounts for nearly 14% of all deaths in the U.S. Mercy has created dedicated programs to keep patients healthier and out of the hospital. One side effect of heart failure is the build of fluid in the feet, ankles and lungs, which can cause breathing problems. Oftentimes, issues from fluid build-up can lead to emergency room visits and multiple-day stays in the hospital. Mercy has piloted fluid management programs to help prevent this and allow patients to return home immediately after treatment.
